Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MDNA 11 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Basal cell cancer; Biliary cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Renal cell carcinoma; Sarcoma; Solid tumours; Squamous cell cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Acronyms ABILITY; ABILITY-1
  • Sponsors Medicenna Therapeutics

    • Most Recent Events

    • 25 Feb 2025 According to a Medicenna Therapeutics media release, the enrollment completion of monotherapy expansion and combination dose escalation is anticipated in mid 2025; initiation of combination dose expansion is also expected in mid 2025, and the addition of several new tumor types will be done in this study.
    • 25 Feb 2025 According to a Medicenna Therapeutics media release, the safety and efficacy results of MDNA11 as a monotherapy and in combination with KEYTRUDA will be presented at medical conferences in H1 2025.
    • 25 Feb 2025 According to a Medicenna Therapeutics media release, the safety review committee has cleared the 120 microgram/kg MDNA11 every 2 weeks in combination with KEYTRUDA as no dose-limiting toxicities (DLTs) have been observed to date.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top